Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Four COVID-19 vaccines just got the FDA's stamp of approval for the 2026–2027 respiratory season, all targeting the dominant XFG variant. The lineup includes two Moderna mRNA shots, Pfizer-BioNTech's Comirnaty, and Novavax/Sanofi's protein-based Nuvaxovid. Coverage is focused on high-risk individuals aged 6 months to 64 years and everyone 65 and older — but a sidelined ACIP means insurance coverage questions remain unresolved.
The FDA has approved four updated COVID-19 vaccines for the 2026–2027 season, all retargeted to the circulating XFG variant. Moderna's Spikevax and the newer lower-dose mNexspike, Pfizer-BioNTech's Comirnaty, and Novavax/Sanofi's protein-based Nuvaxovid are now authorized for high-risk individuals aged 6 months through 64 years and all adults 65 and older. Notably, mNexspike encodes only part of the spike protein at one-fifth the mRNA dose of Spikevax — a meaningful clinical distinction, though no formal guidance exists yet on when to choose one over the other.
The policy backdrop adds complexity. The CDC's ACIP — which normally issues vaccine recommendations that trigger mandatory insurance coverage — has been effectively sidelined following a federal court ruling that HHS Secretary RFK Jr. improperly restructured it. Without ACIP recommendations, free coverage isn't legally guaranteed, though major insurers have pledged to cover all ACIP-recommended vaccines through 2027. COVID-19 infections are currently "very low" but are estimated to be growing in 48 states as of late August.
Key Takeaways:
Why it matters: With ACIP sidelined and insurance coverage in limbo, clinicians and patients face an unusually uncertain vaccine season — even as COVID-19 accounted for up to 2.3 million outpatient visits and 250,000 hospitalizations in the U.S. last year alone.
